Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Liver Transplantation for Cancer: The Future of Transplant Oncology
share announcement

Liver Transplantation for Cancer: The Future of Transplant Oncology

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Transplant Oncology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 2067

Special Issue Editor

Prof. Dr. Tomoharu Yoshizumi

E-Mail Website
Guest Editor
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka City 812-8582, Fukuoka, Japan
Interests: liver; transplantation; hepatocellular carcinoma; cholangiocellular carcinoma; surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a treatment that includes the underlying cirrhosis; theoretically, there is no better treatment. Many studies showed that selected patients with HCC can have improved outcomes after LT. Recently, other hepatobiliary malignancies, such as unresectable perihilar cholangiocarcinoma or liver metastasis for colorectal cancer, have been treated by LT with significant improved outcomes. The concept of such cancer treatment is defined as “transplant oncology”. On the other hand, there are some cautious views that LT for non-HCC malignancies including neuroendocrine tumors should be performed only in high-volume centers under strict selection criteria due to the current shortage of available organs. With this Special Issue, we aim to discuss the selection criteria, pre-LT treatment, appropriate immunosuppressive regimen, and strategies for the follow-up of LT for hepatobiliary malignancies to establish the concept of transplant oncology. 

You may choose our Joint Special Issue in Current Oncology.

Prof. Dr. Tomoharu Yoshizumi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 636 KiB  
Article
Early Results of a Screening Program for Skin Cancer in Liver Transplant Recipients: A Cohort Study
by Delal Akdag, Allan Rasmussen, Susanne Dam Nielsen, Dina Leth Møller, Katrine Togsverd-Bo, Emily Wenande, Merete Haedersdal and Hans-Christian Pommergaard
Cancers 2024, 16(6), 1224; https://doi.org/10.3390/cancers16061224 - 20 Mar 2024
Viewed by 585
Abstract
(1) Background: Skin cancer is the most common cancer in transplant recipients. Timely and regular screening may reduce advanced disease. The study aimed to determine referral rates to screening, the incidence, and risk factors of skin cancer in a Danish liver transplant recipient [...] Read more.
(1) Background: Skin cancer is the most common cancer in transplant recipients. Timely and regular screening may reduce advanced disease. The study aimed to determine referral rates to screening, the incidence, and risk factors of skin cancer in a Danish liver transplant recipient cohort. (2) Methods: All first-time liver transplant recipients, >18 years old, attending outpatient care between January 2018 and December 2021 were included. The referral rates and incidence of skin cancer/preneoplastic lesions were calculated. Risk factors were assessed using Cox regression analyses. (3) Results: Of the 246 included recipients, 219 (89.0%) were referred to screening, and 102 skin cancer/preneoplastic lesions were diagnosed in 32 (15.6%) recipients. The IR of any skin cancer/preneoplastic lesion was 103.2 per 1000 person-years. BCC was the most frequent skin cancer followed by SCC, IR: 51.3 vs. 27.1 per 1000 person-years, respectively. No cases of MM were observed. The IR of actinic keratosis and Bowen’s Disease were 48.1 vs. 13.2 per 1000 person-years, respectively. Time since transplantation was independently associated with skin cancer/preneoplastic lesions, HR (95%CI) 2.81 (1.64–4.80). (4) Conclusions: The study determined the incidence and risk factors of skin cancer/preneoplastic lesions in liver transplant recipients enrolled in a screening program, while demonstrating a high screening referral rate. Full article
(This article belongs to the Special Issue Liver Transplantation for Cancer: The Future of Transplant Oncology)
►▼ Show Figures

Figure 1

14 pages, 1121 KiB  
Article
Declined Organs for Liver Transplantation: A Right Decision or a Missed Opportunity for Patients with Hepatocellular Carcinoma?
by Vladimir J. Lozanovski, Said Adigozalov, Elias Khajeh, Omid Ghamarnejad, Ehsan Aminizadeh, Christina Schleicher, Thilo Hackert, Beat Peter Müller-Stich, Uta Merle, Susanne Picardi, Frederike Lund, De-Hua Chang, Markus Mieth, Hamidreza Fonouni, Mohammad Golriz and Arianeb Mehrabi
Cancers 2023, 15(5), 1365; https://doi.org/10.3390/cancers15051365 - 21 Feb 2023
Cited by 1 | Viewed by 1143
Abstract
Background: Liver transplantation is the only promising treatment for end-stage liver disease and patients with hepatocellular carcinoma. However, too many organs are rejected for transplantation. Methods: We analyzed the factors involved in organ allocation in our transplant center and reviewed all livers that [...] Read more.
Background: Liver transplantation is the only promising treatment for end-stage liver disease and patients with hepatocellular carcinoma. However, too many organs are rejected for transplantation. Methods: We analyzed the factors involved in organ allocation in our transplant center and reviewed all livers that were declined for transplantation. Reasons for declining organs for transplantation were categorized as major extended donor criteria (maEDC), size mismatch and vascular problems, medical reasons and risk of disease transmission, and other reasons. The fate of the declined organs was analyzed. Results: 1086 declined organs were offered 1200 times. A total of 31% of the livers were declined because of maEDC, 35.5% because of size mismatch and vascular problems, 15.8% because of medical reasons and risk of disease transmission, and 20.7% because of other reasons. A total of 40% of the declined organs were allocated and transplanted. A total of 50% of the organs were completely discarded, and significantly more of these grafts had maEDC than grafts that were eventually allocated (37.5% vs. 17.7%, p < 0.001). Conclusion: Most organs were declined because of poor organ quality. Donor-recipient matching at time of allocation and organ preservation must be improved by allocating maEDC grafts using individualized algorithms that avoid high-risk donor-recipient combinations and unnecessary organ declination. Full article
(This article belongs to the Special Issue Liver Transplantation for Cancer: The Future of Transplant Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop